Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2016
NICE publishes second appraisal consultation for Nucala (mepolizumab)
9 June 2016 - NICE has published a second appraisal consultation for GSK's Nucala (mepolizumab). ...
Posted by Michael Wonder on 31 May 2016
Schedule of Pharmaceutical Benefits - 1 June 2016 update
1 June 2016 - The June 2016 issue of the Schedule is out and now in effect. ...
Posted by Michael Wonder on 04 May 2016
Call for patient input on a submission from Teva Pharmaceuticals for reslizumab
4 May 2016 - CADTH has received notice of a pending submission from Teva Pharmaceuticals for reslizumab for use by patients ...
Posted by Michael Wonder on 02 May 2016
Mepolizumab in severe asthma: additional benefit is not proven
2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for mepolizumab (Nucala) for patients with severe eosinophilic asthma
4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in ...
Posted by Michael Wonder on 01 Mar 2016
New Zealand Pharmaceutical Schedule - 1 March 2016 update
1 March 2016 - the March 2016 issue of the Schedule sees the listing of a number of new medicines/combination ...
Posted by Michael Wonder on 14 Dec 2015
Budesonide with eformoterol (Symbicort Turbuhaler and Vannair) proposal with Astra Zeneca
15 December 2015 - PHARMAC is seeking feedback on a proposal involving budesonide with eformoterol inhalers (Symbicort Turbuhaler and Vannair), which ...
Posted by Michael Wonder on 20 Nov 2015
CADTH calls for patient input on a new submission from GSK for mepolizumab
20 November 2015 - CADTH has received notice of a pending submission from GSK for mepolizumab for use by patients with ...
Posted by Michael Wonder on 06 Oct 2015
CADTH calls for patient input on a resubmission for Xolair
7 October 2015 - CADTH has received notice of a pending resubmission for Xolair (omalizumab) for patients with severe peristent asthma. ...